...Hello, and thank you, everybody, for listening in today, and thank you for the introduction. Today, Steve and I will give you an update on Q2 financial overview, along with some of the insights on how the United Therapeutics collaboration will come together in future quarters. And then I'll close it out by a quick update on the pipeline, and then Q&A. So in Q2, I'm really excited. I want to thank everyone at MannKind. We're very excited about the quarter and all the work we've done during Q2 and third quarter year-to-date. Let me start by highlighting our total revenue was up 54% year-over-year, and our Afrezza revenue jumped 43% year-over-year from pre-COVID levels back into the second quarter of 2020. Our orphan lung disease and partnerships are growing rapidly, as we all know about our United Therapeutics collaboration, the end date was submitted in April, accepted by the FDA in June, and we're on track for an October PDUFA date. Our on-site pre-approval inspection was complete as of...